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BACKGROUND: MicroRNAs (miRs) have an important role in lung carcinogenesis and progression. Single-nucleotide polymorphisms
(SNPs) in genes involved in miR biogenesis may affect miR expression in lung tissue and be associated with lung carcinogenesis and
progression.
METHODS: We analysed 12 SNPs in POLR2A, RNASEN and DICER1 genes in 1984 cases and 2073 controls from the Environment And
Genetics in Lung cancer Etiology (EAGLE) study. We investigated miR expression profiles in 165 lung adenocarcinoma (AD) and 125
squamous cell carcinoma tissue samples from the same population. We used logistic and Cox regression models to examine the
association of individual genotypes and haplotypes with lung cancer risk and with lung cancer-specific survival, respectively. SNPs-miR
expression associations in cases were assessed using two-sample t-tests and global permutation tests.
RESULTS: A haplotype in RNASEN (Drosha) was significantly associated with shorter lung cancer survival (hazard ratio¼1.86, 95%
CI¼1.19–2.92, P¼0.007). In AD cases, a SNP within the same haplotype was associated with reduced RNASEN mRNA expression
(P¼0.013) and with miR expression changes (global P¼0.007) of miRs known to be associated with cancer (e.g., let-7 family,
miR-21, miR-25, miR-126 and miR15a).
CONCLUSION: Inherited variation in the miR-processing machinery can affect miR expression levels and lung cancer-specific survival.
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MicroRNAs (miRs) are small non-coding RNAs that bind to the
target transcript in the 30-UTR and can inhibit the translation of
proteins and destabilise their target mRNA (Baek et al, 2008). miRs
are predicted to regulate B30% of the human genome (Lewis et al,
2005) including genes in stress resistance, fat metabolism, cell
proliferation and apoptosis pathways (Ambros, 2003). Polymor-
phisms in miR genes or in genes involved in miR biogenesis
may affect miR-mediated cell regulation (Mishra and Bertino,
2009; Clague et al, 2010). miR biogenesis includes generation of
a primary transcript (pri-miR) under RNA polymerase II
(PolR2A); excision of a stem-loop structure by the nuclear
RNaseIII enzyme (Drosha) to generate the pre-miR; transportation
of the pre-miR to the cytoplasm and processing by another
RNaseIII enzyme (Dicer) into a B22-base mature duplex RNA
(Bartel, 2004). An alteration in any step during the matu-
ration process could affect miR production. Impaired miR
processing and maturation has been shown to enhance cellular
transformation and tumourigenesis (Kumar et al, 2008). Given
the mounting evidence implicating miRs in lung cancer develop-
ment and progression (Yanaihara et al, 2006; Kumar et al, 2008;
Landi et al, 2010), we investigated the role of single-nucleotide
polymorphisms (SNPs) in the RNA-mediated interference
machinery involved in miR maturation in lung cancer.
MATERIALS AND METHODS
We performed SNP genotyping and miR expression profiling
using blood and tumour tissue samples from the Environment
And Genetics in Lung cancer Etiology (EAGLE) study (Landi et al,
2008), including 2100 primary lung cancer cases and
2120 population controls, frequency matched on age, sex and
residence, all Caucasians, enrolled in the Lombardy region of Italy
in 2002–2005. Institutional review boards of the enrolling
hospitals and National Cancer Institute approved the study and
participating subjects signed an informed consent.
Genomic DNA was isolated from blood samples from 1984 cases
and 2073 controls and used to genotype 12 SNPs (Table 1) covering
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sdifferent haplotype blocks in POLR2A, RNASEN (Drosha) and
DICER1 (Figure 1). Genotyping was performed at the Core Geno-
typing Facility, NCI, using TaqMan assays (http://snp500cancer.
nci.nih.gov). Duplicate quality-control samples (2%) showed 100%
agreement in all assays. Subjects with at least a 90% genotype
call-rate (1946 cases, 1982 controls) were included in the final
analyses. All SNPs passed the Hardy–Weinberg equilibrium test
among controls (PX0.26).
The miR expression data were derived from formalin-fixed
paraffin-embedded (FFPE) tissue samples in 165 lung adeno-
carcinoma (AD) and 125 squamous cell carcinoma (SQ) cases
from EAGLE, who had not undergone chemotherapy or radiation
therapy before tissue collection. Lung cancer histology and the
presence of malignant cells in the FFPE tissue blocks were
ascertained by the EAGLE local pathologists and were reviewed by
a pathologist from the NCI. We excluded tissue blocks with mixed
histologies or low frequency of malignant cells. miR expression
profiles were obtained using a custom-made two-channel oligo
array. The miRs represented on the array, data pre-processing,
quality control procedures and selection of the analysed 199
human miRs were described previously (Landi et al, 2010). Array
results were also confirmed by qRT–PCR using Taqman miRNA
assays (Applied Biosystems, Foster City, CA, USA) in 49 samples
from EAGLE that had sufficient tumour miR remaining after the
array analysis (Landi et al, 2010). In addition, we analysed the
association between RNASEN/rs640831 and RNASEN gene expres-
sion in non-involved lung tissue from 45 AD patients from EAGLE
using data from an Affymetrix Chip HG U133A (Affymetrix Inc.,
Santa Clara, CA, USA).
We tested single SNP and haplotype associations with lung
cancer risk in all 3928 subjects and with survival in the 1946 lung
cancer cases. In single SNP analyses, homozygosity for the more
frequent allele among controls was defined as the reference group
and both additive and dominant models were considered. In the
haplotype analyses, the most common haplotype was defined as
the reference group. The associations between variant genotypes
and risk of lung cancer were estimated by odds ratios and their
95% confidence intervals using unconditional logistic regression,
adjusted for categories of age, sex, residence, cumulative smoking
dose (pack-years), smoking intensity (cigarettes per day), and
years-since-quitting smoking. We also performed subgroup
analyses by smoking status (never/ever) and major histology types
and analyses restricted to patients with resectable tumours (stage I,
II and IIIA). Lung cancer-specific survival was defined as time
from diagnosis of lung cancer to time of death due to lung cancer.
Patients who were still alive at the time of last follow-up (n¼439)
or died for causes unrelated to lung cancer (n¼98) were censored
in the analyses. The association of SNPs and haplotypes with
survival-time adjusted for age, sex, stage, and smoking status was
estimated by fitting Cox proportional hazards model (Cox, 1972)
in patients overall and separately for AD and SQ.
We evaluated the association between miR expression and SNPs
within a dominant model in 290 cases using the t-test statistic for
each miR-SNP combination. For each SNP we counted the number of
significant (Pp0.05) miR-SNP associations (ns) and then computed
a global permutation P-value to evaluate the significance of the
association between the SNP and the global miR expression profile.
The permutation test for each SNPi (i¼1, 2, y, 12) was performed
by repeating 9999 times the 199 miRj SNPi
p (j¼1, 2, y, 199)
association t-tests, where each time SNPi
p was a random permuta-
tion across subjects of the original SNPi (P¼1, 2, y, 9999) data and
the number of significant miRj SNPi
p associations (ns
p) was recorded
for each permutation. The global P-value was then defined as one
plus the number of times in which ns
p w a sa tl e a s ta sl a r g ea sn s
(numerator) divided by the total number of permutations plus one
(i.e., denominator¼10000). Finally, we evaluated the association
between RNASEN mRNA expression and the rs640831 SNP with a
dominant model in 45 AD cases using the t-test statistic.
To account for the fact that tests were conducted for 12 different
SNPs and 3 haplotypes, we considered 0.01 as P-value threshold
for statistical significance. All analyses were implemented and performed
using the R-project (v2.10) statistical package (http://www.r-project.org/
index.html) with the exception of the haplotype analysis, conducted
using the THESIAS program (Tregouet and Garelle, 2007).
RESULTS
None of the investigated polymorphisms in POLR2A, RNASEN and
DICER1 showed significant association with lung cancer risk or
lung cancer survival either overall or by subgroups of histology or
smoking status. Analyses based on additive and dominant models
gave similar results (Supplementary Materials 1–8). However, we
found that a RNASEN haplotype, GTAATC (frequency¼2%), was
significantly associated with lung cancer-specific reduced sur-
vival compared with the most common haplotype GTACCT
Table 1 SNPs in the RNA-mediated interference machinery and correlation with miR expression
All samples AD samples SQ samples
Gene SNP Position Alleles MAF Ref. MA miR P-value Ref. MA miR P-value Ref. MA miR P-value
RNASEN rs642321 Chr5:31436760 G:A 0.21 168 108 20 0.125 101 59 15 0.205 67 49 10 0.365
RNASEN rs3805516 Chr5:31456427 T:C 0.22 163 111 25 0.082 97 62 11 0.295 66 49 17 0.155
RNASEN rs493760 Chr5:31472797 A:G 0.29 144 132 3 0.851 77 82 3 0.841 67 50 4 0.795
RNASEN rs640831 Chr5:31495192 C:A 0.34 123 152 30 0.056 68 92 56 0.007 55 60 1 0.985
RNASEN rs7735863 Chr5:31522297 C:T 0.10 223 49 9 0.393 130 26 5 0.656 93 23 9 0.429
RNASEN rs10520985 Chr5:31560322 C:T 0.46 78 193 10 0.351 47 109 10 0.335 31 84 2 0.946
DICER1 rs1209904 Chr14:94633465 G:A 0.26 139 137 4 0.757 80 79 20 0.123 59 58 2 0.944
DICER1 rs2297730 Chr14:94648428 A:G 0.08 230 45 12 0.276 139 19 9 0.393 91 26 6 0.626
POLR2A rs8065577 Chr17:7325898 G:C 0.24 165 112 2 0.929 100 60 3 0.840 65 52 3 0.877
POLR2A rs7217258 Chr17:7336273 A:G 0.28 145 132 5 0.658 87 73 4 0.746 58 59 2 0.944
POLR2A rs2071504 Chr17:7346661 C:T 0.10 215 58 3 0.852 123 34 2 0.928 92 24 9 0.420
POLR2A rs6761 Chr17:7358387 T:C 0.33 123 151 1 0.982 75 83 2 0.927 48 68 2 0.945
Abbreviations: miR¼microRNAs; SNP¼single-nucleotide polymorphism. Gene name, rsID, chromosomal location, major:minor alleles and minor allele frequency (MAF) of the
studied SNPs are reported in the first five columns. The remaining columns show the results for the analysis of correlation between each SNP and the expression of 199 human
miRs using all samples and restricted to adenocarcinoma (AD) and squamous cell carcinoma (SQ) lung cancer tissue samples. For each SNP and analysis type, we reported the
number of subjects homozygous for the most common allele (used as reference and indicated with ‘Ref.’), the number carrying one or two minor variant alleles (indicated with
‘MA’), the number of miRs individually correlated with the SNP at a significant level 0.05 (indicated with ‘miR’), and the global P-value based on 10000 permutations for the
association of the SNP with the miR profile. Bold indicates a significant correlation (global P-value o0.01).
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s(frequency¼30%) among all cases with hazard ratio (HR)¼1.86,
95% CI¼1.19–2.92 and P¼0.007. Similar results were obtained
in AD and SQ histological subtypes (HRs¼2.33, 3.27; 95% CIs¼
1.04–5.25, 1.44–7.43; and P¼0.041, 0.005, respectively) and among
ever smoker patients (HR¼1.81; 95% CI¼1.16–2.82; P¼0.009).
This haplotype-survival association was not observed among the 133
never smoker patients (HR¼0.82; 95% CI¼0.33–2.06; P¼0.679).
When we repeated this analysis among the 821 patients with early
s t a g er e s e c t a b l et u m o u r s( s t a g e ¼I, II and IIIA), the association
between RNASEN haplotype GTAATC and reduced lung cancer-
specific survival was even stronger (HR¼2.36, 95% CI¼1.36–4.09
and P¼0.002). Results were also significant in patients with
resectable AD and resectable SQ separately (HRs¼1.95, 3.99; 95%
CIs¼1.00–3.81, 1.75–9.11; and P¼0.05, 0.001, respectively).
We further studied whether the 12 SNPs were associated
with expression of mature miRs in lung cancer tissue for all
samples and for AD and SQ separately (Table 1). In AD patients,
RNASEN/rs640831, included in the GTACCT haplotype, was
associated with the expression of 56 miRs (global P¼0.007,
Table 2). On average, for subjects who inherited this SNP, 37 miRs
were upregulated and 19 miRs were downregulated in comparison
to subjects with the consensus genotype. miRs with tumour
suppressor potential (e.g., let-7 family) and miRs with oncogenic
or metastatic potential (e.g., miR-21 (Zhu et al, 2008), miR-126
(Crawford et al, 2008) and miR-15a (Cimmino et al, 2005)), were
among those with altered expression in the carriers.
We validated the microarray results by qRT–PCR for 4 of the 56
miRs significantly associated with RNASEN/rs640831 in 49 EAGLE
lung tumour samples. As shown in Supplementary Figure 1, the
correlation was highly significant (P¼0.001, o0.0001, o0.0001,
and 0.002 for let-7g, let-7f, miR-26a and miR-107, respectively).
As expected, the correlation between the microarray and
qRT–PCR data was inverse as qRT–PCR values are measured in
terms of number of measurement cycles needed to reach a certain
expression level: the lower the number of cycles the higher the
detected expression level. In addition, the association between
the expressions as measured by qRT–PCR and RNASEN/rs640831
was qualitatively concordant with the microarray-based results
(inverse association in the 24 AD but not in the 23 SQ cases).
Finally, to further elucidate our finding of a correlation between
the RNASEN/rs640831 and the miR expression profile among AD
cases, we tested the association between RNASEN gene expression
and the rs640831 polymorphism in non-involved lung tissue of
45 AD patients from EAGLE. The 25 AD patients carrying one or
two rs640831 minor variants showed a significantly lower mRNA
expression than the 20 AD patients homozygous with the more
frequent allele (fold change¼0.87, P¼0.013).
DISCUSSION
We have observed (i) an association between lung cancer survival
and a haplotype in RNASEN, particularly, among early stage
patients and (ii) a differentially expressed miR profile and
RNASEN gene expression by RNASEN/rs640831 status in lung
tissue. Carrying the minor variant Av sthe common variant C in
RNASEN/rs640831 contributed to the survival association for the
RNASEN haplotype GTAATC compared with the haplotype
GTACCT. Our results are consistent with the combined effect of
multiple genetic markers within a haplotype as better representing
the impact of the genetic locus on disease progression than
individual markers (Johnson et al, 2001; Crawford and Nickerson,
2005). This is the first evidence that inherited variation in the
miR-processing machinery, more specifically in RNASEN, might
affect survival from lung cancer. Previous studies have shown that
low RNASEN gene expression was associated with survival in
oesophageal cancer patients (Sugito et al, 2006) and, suggestively,
with reduced survival in non-small-cell lung carcinoma patients
(Karube et al, 2005). Our findings provide a possible genetic basis
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Figure 1 SNPs coverage for the Drosha gene. SNPs data available from the HapMap v3 database for the chromosomal region corresponding to the
Drosha gene. The six SNPs studied in this report are shown in the insets, and linkage disequilibrium (r
2) data from HapMap are compared with data in
controls from the EAGLE population showing very similar patterns between the two datasets.
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swas associated with miR expression changes and with lower
RNASEN mRNA expression in AD. Several of these miRs have been
previously reported to be associated with lung cancer survival in
the EAGLE study (Landi et al, 2010) and other lung cancer studies
(Markou et al, 2008; Yu et al, 2008; Raponi et al, 2009). An
analogous global modification of miR profile due to changes in
Table 2 miRs significantly correlated with RNASEN SNP rs640831 in AD patients
MicroRNAs Unique ID P-value Fold change Mean in Ref. (log2) Mean in MA (log2)
Upregulated
has-miR-30b MIMAT0000420 0.0003 1.72  2.60  1.82
hsa-miR-25 MIMAT0000081 0.0011 1.57  2.07  1.41
hsa-miR-92 MIMAT0000092 0.0013 1.51  4.07  3.48
hsa-let-7g MIMAT0000414 0.0016 1.68  2.81  2.06
hsa-miR-21 MIMAT0000076 0.0016 1.89  3.39  2.47
hsa-miR-200c MIMAT0000617 0.0020 1.47 0.90 1.46
hsa-miR-106a MIMAT0000103 0.0020 1.45  4.02  3.48
hsa-miR-30c MIMAT0000244 0.0022 1.68  2.65  1.90
hsa-miR-30a-5p MIMAT0000087 0.0025 1.48  1.18  0.62
hsa-let-7b MIMAT0000063 0.0025 1.50  1.22  0.64
hsa-let-7f MIMAT0000067 0.0031 1.65  2.74  2.02
hsa-miR-181a MIMAT0000256 0.0031 1.38  0.90  0.43
hsa-miR-20b MIMAT0001413 0.0036 1.38  3.52  3.06
hsa-miR-103 MIMAT0000101 0.0036 1.37  1.60  1.14
hsa-miR-98 MIMAT0000096 0.0038 1.62  2.33  1.63
hsa-let-7c MIMAT0000064 0.0040 1.53  1.76  1.15
hsa-miR-20a MIMAT0000075 0.0045 1.45  4.64  4.11
hsa-miR-26a MIMAT0000082 0.0070 1.65  1.01  0.29
hsa-miR-29a MIMAT0000086 0.0071 1.52  1.82  1.22
hsa-miR-126 MIMAT0000445 0.0074 1.55 2.23 2.86
hsa-miR-17-5p MIMAT0000070 0.0096 1.33  3.71  3.30
hsa-miR-107 MIMAT0000104 0.0104 1.30  1.54  1.16
hsa-miR-19b MIMAT0000074 0.0127 1.41  4.20  3.70
hsa-let-7a MIMAT0000062 0.0182 1.40  2.05  1.57
hsa-miR-106b MIMAT0000680 0.0198 1.27  3.32  2.98
hsa-let-7i MIMAT0000415 0.0199 1.39  2.15  1.68
hsa-miR-200b MIMAT0000318 0.0205 1.46 1.67 2.21
hsa-miR-143 MIMAT0000435 0.0205 1.18 0.88 1.12
hsa-miR-26b MIMAT0000083 0.0210 1.39  1.46  0.98
hsa-miR-15a MIMAT0000068 0.0244 1.33  2.04  1.62
hsa-miR-30d MIMAT0000245 0.0281 1.28  0.79  0.44
hsa-miR-93 MIMAT0000093 0.0285 1.30  3.36  2.98
hsa-miR-23a MIMAT0000078 0.0348 1.26 0.36 0.69
hsa-miR-125a MIMAT0000443 0.0377 1.21 0.68 0.96
hsa-miR-22 MIMAT0000077 0.0415 1.30 0.55 0.93
hsa-miR-146b MIMAT0002809 0.0422 1.36  4.46  4.02
hsa-miR-429 MIMAT0001536 0.0432 1.36  0.43 0.02
Downregulated
hsa-miR-452 MIMAT0001635 0.0003 0.88 0.18 0.00
hsa-miR-370 MIMAT0000722 0.0024 0.90 0.41 0.26
hsa-miR-122a MIMAT0000421 0.0037 0.89 0.14  0.03
hsa-miR-130b MIMAT0000691 0.0044 0.92  0.11  0.23
hsa-miR-510 MIMAT0002882 0.0047 0.91 0.22 0.08
hsa-miR-188 MIMAT0000457 0.0065 0.91 0.18 0.04
hsa-miR-509 MIMAT0002881 0.0117 0.86  0.40  0.62
hsa-miR-198 MIMAT0000228 0.0134 0.90 0.43 0.28
hsa-miR-485-5p MIMAT0002175 0.0134 0.90 0.81 0.65
hsa-miR-518c* MIMAT0002847 0.0145 0.89  0.01  0.17
hsa-mir-610 MIMAT0003278 0.0162 0.83 1.01 0.73
hsa-miR-488 MIMAT0002804 0.0166 0.91  0.76  0.90
hsa-miR-453 MIMAT0001630 0.0353 0.93 0.38 0.28
hsa-mir-628 MIMAT0003297 0.0405 0.89  0.14  0.30
hsa-miR-432 MIMAT0002814 0.0420 0.89  0.02 -0.20
hsa-mir-623 MIMAT0003292 0.0429 0.88  0.05  0.24
hsa-miR-299-3p MIMAT0000687 0.0473 0.92 0.05  0.07
hsa-miR-524* MIMAT0002849 0.0473 0.93 0.07  0.03
hsa-miR-383 MIMAT0000738 0.0498 0.91 0.83 0.70
Abbreviations: AD¼adenocarcinoma; miR¼microRNA; SNP¼single-nucleotide polymorphism. The 56 miRs significantly correlated with RNASEN/rs640831 in AD patients are
listed ranking by P-value of each SNP-miR correlation. The analysed miR data is a miR expression intensity ratio between the examined miR and the reference EBV cell line,
followed by median normalisation and log2 base transformation (i.e., a negative value indicates a ratio between 0 and 1). For each miR we also reported the fold change of the
expression ratio for minor allele carriers (indicated with ‘MA’) compared with major allele homozygotes (indicated with ‘Ref.’), and the expression ratio means in the two
compared groups. miRs whose expression has been associated with lung cancer in previous studies are shown in bold. The asterisk (*) symbol after a miR label designates a
complementary miR.
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sDrosha transcript expression level has been observed in cervical
cancer (Muralidhar et al, 2007). A similar finding was not observed
in our analysis restricted to cases with SQ histology, suggesting
that the mechanism by which RNASEN/rs640831 affects miR
expression is specific to AD lung tissues. Such observation is
consistent with previous studies showing that protein levels of
genes involved in the endogenous miR machinery differ between
lung AD and SQ histology subtypes (Chiosea et al, 2007). It is also
possible that the relatively small sample size of the SQ affected the
results.
In contrast to the survival analysis that was based on a large
sample (nB2000), allowing for exploration of several models,
including haplotypes, the miR expression analysis was based on a
smaller sample size (nB300, of which 125 were SQ). Consequently,
only the most informative SNP (MAF¼34%) could be adequately
tested with the miR profile. In contrast, we were not able to detect
possible effects of the full haplotype in association with the miR
profile, because this test would have required hundreds of samples
with miR expression data. Further functional studies and/or larger
miR profiling studies are necessary to confirm our findings.
In conclusion, in the largest study of SNPs in genes involved
in miR biogenesis and lung cancer to date, an inherited variant in
the RNASEN gene, coding for the Drosha enzyme, was associated
with reduced expression of the Drosha gene and changes in the
expression of miRs involved in many cancer-related processes.
A haplotype in Drosha that included the inherited RNASEN
variant and five additional variants was associated with poor lung
cancer survival, particularly, among early stage patients. Drosha
gene variants may affect miR-processing machinery including
miR maturation and expression level, which may consequently
affect the function of miRs in transcript and protein translation
regulation. These variants in Drosha may have potential prognostic
implications in lung cancer.
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